+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 37 Actively Recruiting clinical trials

L

Actively Recruiting

This research aims to provide continued access to niraparib and to further assess its long-term safety in participants with ovarian or breast neoplasms who are currently receiving niraparib treatment within previous GlaxoSmithKlineTESARO-sponsored studies. It focuses on participants who have completed earlier studies where the primary objectives were met and are judged by their doctors to still benefit from niraparib. The study is a phase 2, open-label extension trial designed to monitor treatment continuation and safety over time. Participants will receive niraparib once daily by mouth, following the same dose and schedule as in their previous parent study. Treatment is organized in 90-day cycles and will continue until disease progression, unacceptable side effects, new anticancer therapy unrelated to the parent study, withdrawal, or other reasons for discontinuation occur. The dosing regimen mirrors what was assigned in the prior study, ensuring consistency for each participant. During the study, participants will have regular evaluations to monitor safety and health status for up to five years. These assessments include tracking adverse events, serious side effects, and specific safety concerns, as well as monitoring physical exams, vital signs, blood tests, and medication use. Participants must comply with scheduled visits and treatments while using effective contraception if of childbearing potential. The study duration and follow-up are designed to gather detailed long-term safety information on niraparib treatment.

Age: 18Years +All GendersPhase 2
25 locations
P

Actively Recruiting

Researchers are evaluating a combination therapy of ruxolitinib, steroids, and lenalidomide in adults with relapsed or refractory multiple myeloma MM who have progressive disease despite previous treatments. MM is a cancer of plasma cells in the bone marrow with complex causes and limited curative options. This phase 1, open-label, multicenter study aims to assess the safety and effectiveness of these drugs together in patients who have failed at least two prior therapies including immunomodulatory drugs and proteasome inhibitors. Participants receive varying doses of ruxolitinib orally twice daily, lenalidomide once daily, and methylprednisolone every other day. The study includes dose escalation periods and treatment adjustments based on disease progression. Some groups start with ruxolitinib and steroids, adding lenalidomide only if the disease worsens. Treatment continues until disease progression or unacceptable side effects occur. During the study, participants will have regular evaluations including blood tests and clinical assessments to monitor safety, side effects, and treatment response. Researchers will measure outcomes such as the maximum tolerated dose, adverse events, response rates, progression-free and overall survival over a follow-up period extending up to 54 months. Participants are expected to adhere to visit schedules and study requirements throughout the trial.

Age: 18Years +All GendersPhase 1
13 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ENV-294, an oral investigational drug, in adults with moderate-to-severe atopic dermatitis AD. This double-blind, placebo-controlled Phase 2b study compares three different doses of ENV-294 against a placebo over 12 weeks. The study aims to better understand how ENV-294 affects disease severity, symptoms, quality of life, and biological markers in people with chronic AD. Participants will be randomly assigned to one of four groups receiving either one of three doses of ENV-294 or a matching placebo. The treatment is taken once daily by mouth for 12 weeks. Before starting treatment, participants undergo screening to confirm eligibility based on their AD diagnosis, disease severity, and treatment history. During the study, participants complete regular assessments of their eczema severity using standardized scores like the Eczema Area and Severity Index EASI, patient-reported outcomes, safety checks, blood tests for drug levels, and biomarker analysis. Researchers monitor for any adverse events throughout the 12 weeks and for an additional 4 weeks following treatment. The total participation time includes screening, treatment, and follow-up assessments to evaluate both the effects and safety of ENV-294.

Age: 18Years +All GendersPhase 2
9 locations
L

Actively Recruiting

Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.

Age: 18Years - 50YearsFEMALEPhase 3
120 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of targeted therapies and immunotherapy, either alone or in combination, for patients with metastatic colorectal cancer mCRC whose tumors test positive for specific biomarkers. This open-label, Phase 11b study enrolls participants into different treatment groups based on their biomarker test results to explore personalized treatment approaches. Participants receive various combinations of study drugs, including oral medications like inavolisib and divarasib and intravenous infusions such as cetuximab, bevacizumab, atezolizumab, tiragolumab, SY-5609, FOLFOX, and FOLFIRI chemotherapy. Treatment cycles vary from 21 to 28 days depending on the assigned treatment arm, with dosing schedules including daily oral medications and infusions given weekly, every two weeks, or every three weeks. Some treatment arms are closed or not recruiting, while others remain active. Throughout the study, participants undergo regular assessments including tumor imaging to measure response, blood tests, and biomarker sampling. Researchers monitor outcomes such as objective response rate, disease control, duration of response, and adverse events over approximately 84 months. Participants overall health and tumor status are closely followed to evaluate treatment effects and safety during and after therapy.

Age: 18Years +All GendersPhase 1
84 locations
S

Actively Recruiting

This research aims to learn about the safety and effects of a medicine called ritlecitinib for treating moderate alopecia areata AA, a condition causing patchy hair loss. The study includes participants aged 12 years and older who have had patchy hair loss for at least 6 months but not more than 10 years, without other causes of hair loss. It is a phase 3 randomized, double-blind, placebo-controlled trial designed to evaluate ritlecitinib in adolescents and adults with AA. Participants will be randomly assigned to receive either ritlecitinib 50 mg or placebo once daily by mouth for 24 weeks. After this, depending on their response, their treatment may remain the same or change to either 50 mg or 100 mg ritlecitinib for another 23 weeks. Those receiving placebo initially may also be switched to ritlecitinib during this second period. Treatments are taken at home, and the study includes multiple groups based on response to treatment. Participants will be involved for about 57 weeks, including study visits at the clinic and some phone check-ins. Researchers will monitor hair loss using the Severity of Alopecia Tool SALT and other assessments like eyebrow and eyelash evaluations, patient satisfaction, and emotional impact. Safety will be closely monitored through adverse event tracking and laboratory tests. A follow-up visit about 4 weeks after the last dose will check on participants health.

Age: 12Years +All GendersPhase 3
38 locations
R

Actively Recruiting

Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.

Age: 12Years +All GendersPhase 3
148 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of baricitinib in treating severe or very severe alopecia areata, a type of hair loss, in children aged 6 to less than 18 years. This Phase 3 trial includes children and adolescents with severe alopecia areata lasting at least one year and aims to understand how baricitinib helps improve their condition compared to placebo. Participants will be randomly assigned to one of three groups baricitinib high dose, baricitinib low dose, or placebo, all taken orally. The study includes a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week post-treatment follow-up. Some participants may qualify for additional treatment after the extension period lasting up to 180 weeks. During the study, participants will have regular assessments including hair loss severity scores, patient and clinician reported outcomes, anxiety and depression scales, and pharmacokinetic tests. Safety and effects on quality of life will be monitored throughout, with follow-ups after treatment ends. Total participation may last several years depending on the study phase and extension.

Age: 6Years - 17YearsAll GendersPhase 3
127 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are conducting a phase 3 clinical trial to study adults with moderate or severe abdominal subcutaneous fat. The trial aims to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared to a placebo in reducing abdominal fat. Approximately 320 participants will be enrolled to better understand how well this treatment works and how safe it is for reducing fat under the skin in the abdominal area. Participants will be randomly assigned to receive either the CBL-514 injection or a placebo 0.9% Sodium Chloride solution. Each participant can receive up to four treatments, with injections administered subcutaneously to the abdomen at four-week intervals. Both groups will receive up to 120 mL per treatment, delivered through 50 injections each time. During the study, participants will undergo assessments including patient and clinician reports on abdominal fat levels, measured from the start of the study to four weeks after the final treatment. Researchers will monitor changes in abdominal fat and improvements on rating scales. Participants will also be evaluated for safety and tolerability throughout the trial, which is expected to last until September 2027.

Age: 18Years +All GendersPhase 3
13 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with type 2 diabetes mellitus T2DM who have an increased cardiovascular risk. This study focuses on patients whose diabetes is not adequately controlled with lifestyle changes or stable glucose-lowering medications. The trial is a Phase III, randomized, open-label, parallel-group study sponsored by AstraZeneca. Participants will be randomly assigned to receive either elecoglipron or semaglutide, both administered orally once daily at specified doses. The treatment period lasts up to 52 weeks, during which the effects of these medications on blood sugar control and other health measures will be assessed. Throughout the study, participants will undergo regular evaluations including measurements of hemoglobin A1c HbA1c, body weight, and blood pressure at baseline and at 52 weeks. Researchers will monitor changes in these parameters to assess the impact of the treatments. Safety and tolerability will also be closely followed during the trial period.

Age: 18Years +All GendersPhase 3
210 locations

1-10 of 37

1